Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.
作者信息
Hertz Daniel L, McShane Lisa M, Hayes Daniel F
机构信息
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD.
出版信息
J Clin Oncol. 2022 Jun 1;40(16):1721-1731. doi: 10.1200/JCO.21.02209. Epub 2022 Mar 24.
Abstract
摘要
相似文献
1
Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.
J Clin Oncol. 2022 Jun 1;40(16):1721-1731. doi: 10.1200/JCO.21.02209. Epub 2022 Mar 24.
2
Using germline genotype in cancer pharmacogenetic studies.
Pharmacogenomics. 2009 Mar;10(3):489-93. doi: 10.2217/14622416.10.3.489.
3
Moratorium for germline editing splits biologists.
Science. 2019 Mar 15;363(6432):1130-1131. doi: 10.1126/science.363.6432.1130.
4
Understanding what determines the frequency and pattern of human germline mutations.
Nat Rev Genet. 2009 Jul;10(7):478-88. doi: 10.1038/nrg2529.
5
The risks of germline gene transfer.
Hastings Cent Rep. 2003 Mar-Apr;33(2):3.
6
Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
7
Accident & desire. Inadvertent germline effects in clinical research.
Hastings Cent Rep. 2003 Mar-Apr;33(2):23-30.
8
Challenges of Accuracy in Germline Clinical Sequencing Data.
JAMA. 2021 Jul 20;326(3):268-269. doi: 10.1001/jama.2021.0407.
9
The repertoire of germline variants in patients with early-onset rectal cancer.
Cancer Commun (Lond). 2022 May;42(5):481-485. doi: 10.1002/cac2.12262. Epub 2022 Jan 14.
10
Germline edits: Heat does not help debate.
Nature. 2015 Apr 30;520(7549):623. doi: 10.1038/520623a.
引用本文的文献
1
Potential association of and variant alleles with increased risk for palbociclib toxicity.
Pharmacogenomics. 2024;25(8-9):367-375. doi: 10.1080/14622416.2024.2380240. Epub 2024 Aug 2.
2
Systemic inflammation and cancer-related frailty: shifting the paradigm toward precision survivorship medicine.
ESMO Open. 2024 Jan;9(1):102205. doi: 10.1016/j.esmoop.2023.102205. Epub 2024 Jan 9.
3
Checkpoint inhibitors and anti-angiogenic agents: a winning combination.
Br J Cancer. 2023 Oct;129(9):1367-1372. doi: 10.1038/s41416-023-02437-1. Epub 2023 Sep 21.
4
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer.
Pharmaceutics. 2023 Feb 15;15(2):651. doi: 10.3390/pharmaceutics15020651.
本文引用的文献
1
Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.
JCO Precis Oncol. 2019 Dec;3:1-10. doi: 10.1200/PO.19.00210.
2
Clinical Utility of Genomic Testing in Cancer Care.
JCO Precis Oncol. 2022 Jan;6:e2100349. doi: 10.1200/PO.21.00349.
3
Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing.
Genet Med. 2021 Dec;23(12):2335-2341. doi: 10.1038/s41436-021-01269-9. Epub 2021 Jul 19.
4
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN).
Cancer Treat Rev. 2021 Sep;99:102241. doi: 10.1016/j.ctrv.2021.102241. Epub 2021 Jun 9.
5
Moving Pharmacogenetics Into Practice: It's All About the Evidence!
Clin Pharmacol Ther. 2021 Sep;110(3):649-661. doi: 10.1002/cpt.2327. Epub 2021 Jul 7.
6
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
7
Analysis Approaches to Identify Pharmacogenetic Associations With Pharmacodynamics.
Clin Pharmacol Ther. 2021 Sep;110(3):589-594. doi: 10.1002/cpt.2312. Epub 2021 Jun 28.
8
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.
Support Care Cancer. 2021 Aug;29(8):4269-4275. doi: 10.1007/s00520-020-05977-x. Epub 2021 Jan 7.
9
Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.
J Clin Oncol. 2021 Jan 20;39(3):238-248. doi: 10.1200/JCO.20.01572. Epub 2020 Dec 16.
10
Clinical utility of genomic sequencing: a measurement toolkit.
NPJ Genom Med. 2020 Dec 15;5(1):56. doi: 10.1038/s41525-020-00164-7.
Zotero 插件